‘A tracer is still a drug’: a potential medicines-recording blind spot in nuclear medicine

Derek Dale Ang Bayquen, Ana Aguiar, Katie Morris, Kate McElligott

Open source

DOI
10.1097/mnm.0000000000002251
Published
2026-10-26
Container
Nuclear Medicine Communications
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/mnm.0000000000002251,
  title = {‘A tracer is still a drug’: a potential medicines-recording blind spot in nuclear medicine},
  author = {Derek Dale Ang Bayquen and Ana Aguiar and Katie Morris and Kate McElligott},
  year = {2026},
  journal = {Nuclear Medicine Communications},
  doi = {10.1097/mnm.0000000000002251},
  url = {https://doi.org/10.1097/mnm.0000000000002251}
}

RIS

TY  - JOUR
TI  - ‘A tracer is still a drug’: a potential medicines-recording blind spot in nuclear medicine
AU  - Derek Dale Ang Bayquen
AU  - Ana Aguiar
AU  - Katie Morris
AU  - Kate McElligott
PY  - 2026
JO  - Nuclear Medicine Communications
DO  - 10.1097/mnm.0000000000002251
UR  - https://doi.org/10.1097/mnm.0000000000002251
ER  - 

APA

Bayquen, D. D. A., Aguiar, A., Morris, K., & McElligott, K. (2026). ‘A tracer is still a drug’: a potential medicines-recording blind spot in nuclear medicine. Nuclear Medicine Communications. https://doi.org/10.1097/mnm.0000000000002251

Source records